Source: FDA, National Drug Code (US) Revision Year: 2020
DAYVIGO contains lemborexant, an orexin receptor antagonist. The chemical name of lemborexant is (1R,2S)2{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}2(3-fluorophenyl)N(5-fluoropyridin-2-yl) cyclopropanecarboxamide. The molecular formula is C22H20F2N4O2. The molecular weight is 410.42.
The structural formula is:
Lemborexant is a white to off-white powder that is practically insoluble in water.
DAYVIGO tablets are intended for oral administration. Each film coated tablet contains 5 mg or 10 mg of lemborexant. The inactive ingredients are: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, and magnesium stearate.
In addition, the film coating contains the following inactive ingredients: hypromellose 2910, polyethylene glycol 8000, talc, titanium dioxide, and either (a) ferric oxide yellow for the 5 mg tablet; or, (b) both ferric oxide yellow and ferric oxide red for the 10 mg tablet.
Dosage Forms and Strengths |
---|
DAYVIGO (lemborexant) tablets are available as:
|
How Supplied |
---|
DAYVIGO tablets are available as:
NDC 62856-405-30, bottle of 30 with child-resistant closure
NDC 62856-410-30, bottle of 30 with child-resistant closure |
Drug | Countries | |
---|---|---|
DAYVIGO | Canada, Hong Kong, Israel, Japan, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.